Limits...
Detection and characterization of liver lesions using gadoxetic acid as a tissue-specific contrast agent.

Reimer P, Vosshenrich R - Biologics (2010)

Bottom Line: Gadoxetic acid enhances hepatocyte-containing lesions and improves detection of lesions devoid of normal hepatocytes, such as metastases.Innovative rapid MR acquisition techniques with near isotropic 3D pulse sequences with fat saturation parallel the technical progress made by multidetector computed tomography combined with an impressive improvement in tumor-liver contrast when used for gadoxetic acid-enhanced MRI.The purpose of this review is to provide an overview of the development, clinical testing, and applications of this novel MR contrast agent.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Klinikum Karlsruhe, Karlsruhe, Germany;

ABSTRACT
The value of cross-sectional liver imaging is evaluated by the accuracy, sensitivity, and specificity of the specific imaging technique. Magnetic resonance imaging (MRI) has become a key technique for the characterization and detection of focal and diffuse liver disease. More recently, gadoxetic acid, the hepatocyte-specific MR contrast agent, was clinically approved and introduced in many countries. Gadoxetic acid may be considered a "molecular imaging" probe because the compound is actively taken into hepatocytes via the ATP-dependent organic anion transport system in the plasma membrane for the hepatic uptake. The transport of gadoxetic acid from the cytoplasm to the bile is mainly determined by the capacity of the transport protein glutathione-S-transferase. Gadoxetic acid enhances hepatocyte-containing lesions and improves detection of lesions devoid of normal hepatocytes, such as metastases. Innovative rapid MR acquisition techniques with near isotropic 3D pulse sequences with fat saturation parallel the technical progress made by multidetector computed tomography combined with an impressive improvement in tumor-liver contrast when used for gadoxetic acid-enhanced MRI. The purpose of this review is to provide an overview of the development, clinical testing, and applications of this novel MR contrast agent.

No MeSH data available.


Related in: MedlinePlus

Anaplastic hepatocellular carcinoma (HCC) following radioembolization. Plain T1-weighted spoiled 2D gradient echo (GRE) A) T2-weighted half-Fourier acquisition single-shot turbo spin-echo (HASTE) B) diffusion-weighted imaging (DWI) C) and hepatocellular phase gadoxetic acid-enhanced fat-suppressed (FS) T1-weighted spoiled 3D GRE D) in the axial plane. The large hypointense zone in segment 8 resembles an area following radioembolization of the previously more circumscribed tumor. Multiple new satellite tumors can only be appreciated on gadoxetic acid-enhanced MRI.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2921257&req=5

f4-btt-4-199: Anaplastic hepatocellular carcinoma (HCC) following radioembolization. Plain T1-weighted spoiled 2D gradient echo (GRE) A) T2-weighted half-Fourier acquisition single-shot turbo spin-echo (HASTE) B) diffusion-weighted imaging (DWI) C) and hepatocellular phase gadoxetic acid-enhanced fat-suppressed (FS) T1-weighted spoiled 3D GRE D) in the axial plane. The large hypointense zone in segment 8 resembles an area following radioembolization of the previously more circumscribed tumor. Multiple new satellite tumors can only be appreciated on gadoxetic acid-enhanced MRI.

Mentions: Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide (Figures 3 and 4). Most of the HCCs that are associated with hepatitis B virus (HBV) occur in patients who have hepatitis B infection during most of their lives, also called chronic hepatitis B. The development of HCC is also associated with chronic hepatitis C virus (HCV). Most of the patients who develop HCC as a result of HCV will have liver cirrhosis. The average time to develop HCC after initial exposure to HCV is about 28 years and usually about 8–10 years after the development of liver cirrhosis. The way in which HCV causes HCC is not well understood.4


Detection and characterization of liver lesions using gadoxetic acid as a tissue-specific contrast agent.

Reimer P, Vosshenrich R - Biologics (2010)

Anaplastic hepatocellular carcinoma (HCC) following radioembolization. Plain T1-weighted spoiled 2D gradient echo (GRE) A) T2-weighted half-Fourier acquisition single-shot turbo spin-echo (HASTE) B) diffusion-weighted imaging (DWI) C) and hepatocellular phase gadoxetic acid-enhanced fat-suppressed (FS) T1-weighted spoiled 3D GRE D) in the axial plane. The large hypointense zone in segment 8 resembles an area following radioembolization of the previously more circumscribed tumor. Multiple new satellite tumors can only be appreciated on gadoxetic acid-enhanced MRI.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2921257&req=5

f4-btt-4-199: Anaplastic hepatocellular carcinoma (HCC) following radioembolization. Plain T1-weighted spoiled 2D gradient echo (GRE) A) T2-weighted half-Fourier acquisition single-shot turbo spin-echo (HASTE) B) diffusion-weighted imaging (DWI) C) and hepatocellular phase gadoxetic acid-enhanced fat-suppressed (FS) T1-weighted spoiled 3D GRE D) in the axial plane. The large hypointense zone in segment 8 resembles an area following radioembolization of the previously more circumscribed tumor. Multiple new satellite tumors can only be appreciated on gadoxetic acid-enhanced MRI.
Mentions: Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide (Figures 3 and 4). Most of the HCCs that are associated with hepatitis B virus (HBV) occur in patients who have hepatitis B infection during most of their lives, also called chronic hepatitis B. The development of HCC is also associated with chronic hepatitis C virus (HCV). Most of the patients who develop HCC as a result of HCV will have liver cirrhosis. The average time to develop HCC after initial exposure to HCV is about 28 years and usually about 8–10 years after the development of liver cirrhosis. The way in which HCV causes HCC is not well understood.4

Bottom Line: Gadoxetic acid enhances hepatocyte-containing lesions and improves detection of lesions devoid of normal hepatocytes, such as metastases.Innovative rapid MR acquisition techniques with near isotropic 3D pulse sequences with fat saturation parallel the technical progress made by multidetector computed tomography combined with an impressive improvement in tumor-liver contrast when used for gadoxetic acid-enhanced MRI.The purpose of this review is to provide an overview of the development, clinical testing, and applications of this novel MR contrast agent.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Klinikum Karlsruhe, Karlsruhe, Germany;

ABSTRACT
The value of cross-sectional liver imaging is evaluated by the accuracy, sensitivity, and specificity of the specific imaging technique. Magnetic resonance imaging (MRI) has become a key technique for the characterization and detection of focal and diffuse liver disease. More recently, gadoxetic acid, the hepatocyte-specific MR contrast agent, was clinically approved and introduced in many countries. Gadoxetic acid may be considered a "molecular imaging" probe because the compound is actively taken into hepatocytes via the ATP-dependent organic anion transport system in the plasma membrane for the hepatic uptake. The transport of gadoxetic acid from the cytoplasm to the bile is mainly determined by the capacity of the transport protein glutathione-S-transferase. Gadoxetic acid enhances hepatocyte-containing lesions and improves detection of lesions devoid of normal hepatocytes, such as metastases. Innovative rapid MR acquisition techniques with near isotropic 3D pulse sequences with fat saturation parallel the technical progress made by multidetector computed tomography combined with an impressive improvement in tumor-liver contrast when used for gadoxetic acid-enhanced MRI. The purpose of this review is to provide an overview of the development, clinical testing, and applications of this novel MR contrast agent.

No MeSH data available.


Related in: MedlinePlus